Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H20ClF3N2O.ClH |
| Molecular Weight | 433.295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]1(CCCCN1)[C@@H](NC(=O)C2=C(Cl)C(=CC=C2)C(F)(F)F)C3=CC=CC=C3
InChI
InChIKey=YGCZZYKACZXKHK-AKXYIILFSA-N
InChI=1S/C20H20ClF3N2O.ClH/c21-17-14(9-6-10-15(17)20(22,23)24)19(27)26-18(13-7-2-1-3-8-13)16-11-4-5-12-25-16;/h1-3,6-10,16,18,25H,4-5,11-12H2,(H,26,27);1H/t16-,18-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H20ClF3N2O |
| Molecular Weight | 396.834 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + ) |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour. | 2009 Aug |
|
| SSR504734, a glycine transporter-1 inhibitor, attenuates acquisition and expression of contextual conditioned fear in rats. | 2010 Sep |
|
| Pharmacological characterization of [³H]CHIBA-3007 binding to glycine transporter 1 in the rat brain. | 2011 |
|
| Amino-terminal isoforms of the human glycine transporter GlyT1 exhibit similar pharmacology. | 2011 Feb 16 |
|
| Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. | 2011 Jul-Aug |
|
| Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse. | 2011 Jun |
|
| In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. | 2011 May |
|
| Synthesis and evaluation of 2-chloro N-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl]3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET radioligand for glycine transporter 1. | 2012 Jul 9 |
|
| Brain-specific disruption of the eIF2α kinase PERK decreases ATF4 expression and impairs behavioral flexibility. | 2012 Jun 28 |
|
| SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine. | 2013 Nov |
|
| Inhibition of glycine transporter-1 reduces cue-induced nicotine-seeking, but does not promote extinction of conditioned nicotine cue responding in the rat. | 2013 Sep |
|
| Involvement of the strychnine-sensitive glycine receptor in the anxiolytic effects of GlyT1 inhibitors on maternal separation-induced ultrasonic vocalization in rat pups. | 2015 Jan 5 |
|
| Discovery of 3-Chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor. | 2016 |
|
| Targeting Glycine Reuptake in Alcohol Seeking and Relapse. | 2018 Apr |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:34 GMT 2023
by
admin
on
Sat Dec 16 11:40:34 GMT 2023
|
| Record UNII |
L297UZF32G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
615571-23-8
Created by
admin on Sat Dec 16 11:40:34 GMT 2023 , Edited by admin on Sat Dec 16 11:40:34 GMT 2023
|
PRIMARY | |||
|
9954539
Created by
admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
|
PRIMARY | |||
|
L297UZF32G
Created by
admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
|
PRIMARY | |||
|
300000042454
Created by
admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
We examined the effect of GlyT1 inhibitor SSR-504734 on cognitive flexibility assessed in the attentional set-shifting task in rats (ASST). The second goal was to elucidate whether SSR-504734 effect has been due to the compound's action at glycine/NMDAR site. Rats treated with SSR-504734 (3 and 10 mg/kg, IP) required significantly less trials to criteria during extra-dimensional shift (EDs) phase of the ASST. The effect of SSR-504734 (3 mg/kg) was completely prevented by the glycine/NMDAR site antagonist, L-687,414 (30 mg/kg, IP) that by itself exerted no effect on cognitive flexibility. It is suggested that GlyT1 inhibitors like SSR-504734 may represent a useful pharmacological approach for cognitive enhancement, especially in domains critically affected in schizophrenia.
|
||
|
ACTIVE MOIETY |
Class: Antipsychotic; Mechanism of Action: Glycine transporter 1 inhibitor; Highest Development Phase: Discontinued for Schizophrenia
|
||
|
ACTIVE MOIETY |
Adult rats spent more time exploring the novel than the familiar juvenile. This capacity for social novelty discrimination was impaired in rats that received neonatal PCP treatment and the impaired discrimination could be reversed by acute treatment with antipsychotic drugs such as clozapine (0.3-3 mg/kg) and the glycine transporter GlyT1 inhibitor SSR-504734 (1-10 mg/kg).
|